Unlike general biomarker services, we tailor our approach specifically to inflammatory mechanisms underlying HLH-like syndromes in engineered cell therapy settings.
Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
As immune effector cell therapies, including CAR-T and TCR-engineered platforms, continue to redefine the therapeutic landscape, understanding and managing their associated immunotoxicities becomes a critical priority. Among the most complex of these is Immune Effector Cell-associated HLH-like Syndrome (IEC-HS)—a hyperinflammatory condition that shares key features with macrophage activation, immune dysregulation, and systemic cytokine escalation.
While phenotypic, cytokine, and transcriptomic profiling help describe the immune environment, biomarker discovery offers a translational bridge—linking immune dynamics with measurable molecular readouts. Validated biomarkers can serve as early indicators of dysregulated immune cascades, functional surrogates of therapeutic stress, or even targets for future mitigation strategies.
Creative Biolabs has developed a dedicated IEC-HS Biomarker Discovery Service to support researchers in identifying, validating, and prioritizing novel biomarkers associated with HLH-like responses in the context of CAR-based or other engineered immune effector cell therapies. Our solution is purpose-built for preclinical discovery and mechanism-focused research, enabling precise dissection of IEC-HS onset and trajectory across various model systems.
Our IEC-HS Biomarker Discovery platform integrates multiple analytical dimensions—protein expression, transcript signatures, cell surface phenotypes, metabolic stress markers, and pathway-centric features—to deliver a full-spectrum view of candidate biomarkers.
Unlike general biomarker services, we tailor our approach specifically to inflammatory mechanisms underlying HLH-like syndromes in engineered cell therapy settings.
Protein, gene, surface, and metabolite-level discovery allow flexible entry points depending on study goals and sample availability.
Compatible with existing genomic or flow datasets—supports longitudinal tracking and cross-assay validation.
Supports both human and murine samples, enabling translational bridge from preclinical modeling to eventual human application.
Start with targeted discovery, then scale into customized biomarker panels or support multiplex assay development.
Q1: Can I submit previously generated data for biomarker re-analysis?
A1: Yes. We offer standalone bioinformatics support to re-analyze transcriptomic or proteomic data for IEC-HS-specific biomarker discovery.
Q2: Do you support discovery in murine models?
A2: Absolutely. Our platform is fully validated for mouse models, and we can align findings across species to identify conserved biomarker signatures.
Q3: Can you help us develop a custom biomarker panel post-discovery?
A3: Yes. We offer downstream panel development services, including multiplex assay design based on your candidate list.
Q4: What sample types do you accept?
A4: We work with a wide range of samples including serum, plasma, cell culture supernatants, cell pellets, or purified immune cell populations.
Q5: Is this service intended for diagnostic use?
A5: No. All services provided are strictly for research use only and not for clinical or diagnostic applications.
Biomarker discovery is essential for transforming complex immune responses into actionable scientific insights. At Creative Biolabs, our IEC-HS Biomarker Discovery Service provides the depth, flexibility, and scientific guidance needed to uncover new molecular correlates of HLH-like events and expand the toolset for CAR-T immunotoxicity research.
Uncover the molecular signatures behind immune complexity. Partner with Creative Biolabs to accelerate your biomarker discovery pipeline.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
